Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection

References

• Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;300:1436–9.
   Google Scholar
• Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheuma-toid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706–11.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986–92.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF, et al. Tuberculosis associated with therapy against tumor necrosis factor a. Arthritis Rheum. 2005;52:2968–74.
   PubMedGoogle Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with inflix-imab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
   Google Scholar
• Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antago-nists. Arthritis Rheum. 2005;52:1766–72.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheuma-tol. 2007;17:451–8.
   Google Scholar
• Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
   PubMed Web of Science ®Google Scholar
• Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149: 689–97.
   Google Scholar
• Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.
   Google Scholar
• Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, et al. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest. 2008;133:1196–202.
   PubMed Web of Science ®Google Scholar
• Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med. 2004;170:59–64.
   PubMed Web of Science ®Google Scholar
• Maekura R, Okuda Y, Nakagawa M, Hiraga T, Yokota S, Ito M, et al. Clinical evaluation of anti-tuberculous glycolipid immu-noglobulin G antibody assay for rapid serodiagnosis of pulmon-ary tuberculosis. J Clin Microbiol. 2001;39:3603–8.
   PubMed Web of Science ®Google Scholar
• Kawamura M, Sueshige N, Imayoshi K, Yam I, Maekura R, Kohno H. Enzyme immunoassay to detect antituberculous gly-colipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis. J Clin Lab Anal. 1997;11:140–5.
   PubMed Web of Science ®Google Scholar
• Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Tones A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in popula-tion with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360–1.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Sood S. QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis? Ann Rheum Dis. 2007;66:276.
   Google Scholar
• Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008;3:776–81.
   Google Scholar
• Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford). 2007;46:1035–6.
   Google Scholar
• Wu-Hsieh BA, Chen CK, Chang JH, Lai SY, Wu CH, Cheng WC, et al. Long-lived immune response to early secretory anti-genic target 6 in individuals who had recovered from tubercu-losis. Clin Infect Dis 2001;33: 1336–40.
   Google Scholar
• Kobashi Y, Sugiu T, Ohue Y, Mouri K, Obase Y, Miyashita N, et al. Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease. Intern Med. 2008;47:1957–61.
   PubMed Web of Science ®Google Scholar
• Emery P, Panayi GS, Noun i AM. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol. 1984;57:123–9.
   Google Scholar